10-Q/A: Cardiff Lexington Reports Wider Q1 Loss Amid Rising Costs

Cardiff Lexington Corporation filed an amended quarterly report revealing a wider net loss for Q1 2025 despite revenue growth, driven by increased operating expenses and interest costs.

Summary

• Cardiff Lexington Corporation filed an amended Form 10-Q/A for the quarter ended March 31, 2025, primarily to correct a classification error of non-cash interest expense in its cash flow statements.
• Revenue for the three months ended March 31, 2025, increased by 25.56% to $2,915,567, up from $2,322,132 in the prior year, driven by higher patient volume and more complex medical procedures in its healthcare segment.
• Gross profit rose by 33.96% to $1,840,533, with the gross margin improving to 63.13% from 59.17% year-over-year.
• Operating expenses increased by 12.26% to $1,296,599, primarily due to a 50.42% surge in selling, general, and administrative expenses, which reached $1,280,641.
• The increase in selling, general, and administrative expenses was mainly attributable to higher salaries and wages ($255,387 increase), bad debt expense ($112,727 increase), and billing costs ($57,735 increase).
• Interest expense significantly increased to $993,114 for Q1 2025, compared to $376,269 for Q1 2024.
• The net loss for the period widened by 59.23% to $(450,777) in Q1 2025, from $(283,104) in Q1 2024.
• Net loss attributable to common shareholders increased to $(696,222) from $(434,738) in the prior year.
• Basic and diluted loss per share from continuing operations improved to $(0.05) in Q1 2025 from $(0.11) in Q1 2024, primarily due to a substantial increase in weighted average shares outstanding to 15,315,657 from 3,818,218.
• Cash balance decreased to $996,758 as of March 31, 2025, from $1,188,185 at December 31, 2024.
• Net cash used in operating activities improved to $(491,420) in Q1 2025, compared to $(1,035,021) in Q1 2024.
• Net cash provided by financing activities decreased significantly to $299,993 in Q1 2025, from $1,310,318 in Q1 2024.
• The company's accumulated deficit grew to $(73,645,307) as of March 31, 2025.
• The maximum advance amount on the revolving line of credit with DML HC Series, LLC was increased to $15,000,000, with $10,210,485 outstanding as of March 31, 2025.
• The company continues to operate under a 'going concern' doubt, requiring additional capital infusions for continued operations and acquisitions.
• Material weaknesses in internal control over financial reporting are still being remediated.

Sentiment

Score: 3

Explanation: While revenue growth and gross margin improvement are positive, these are overshadowed by a significantly widening net loss, a substantial increase in interest expense, declining cash reserves, and an explicit 'going concern' warning. The company's high accumulated deficit and ongoing need for significant capital raises indicate severe financial instability and high investment risk, despite management's efforts to secure funding and improve operations.

Positives

• Revenue increased by 25.56% to $2,915,567 for the three months ended March 31, 2025, indicating strong top-line growth.
• Gross profit increased by 33.96% to $1,840,533, and gross margin improved to 63.13% from 59.17%, demonstrating better cost management relative to revenue.
• Net cash used in operating activities significantly decreased to $(491,420) in Q1 2025 from $(1,035,021) in Q1 2024, indicating improved operational cash efficiency.
• The maximum advance amount on the revolving line of credit was increased to $15,000,000, providing additional liquidity capacity.
• Loss per share from continuing operations improved to $(0.05) from $(0.11), although this is influenced by increased share count.

Negatives

• Net loss for the period widened by 59.23% to $(450,777) in Q1 2025, compared to $(283,104) in Q1 2024.
• Interest expense more than doubled to $993,114 in Q1 2025 from $376,269 in Q1 2024, significantly impacting profitability.
• Cash balance decreased to $996,758 as of March 31, 2025, from $1,188,185 at December 31, 2024.
• The company has an accumulated deficit of $(73,645,307) as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Selling, general and administrative expenses increased by 50.42%, outpacing revenue growth.
• Net cash provided by financing activities decreased significantly, indicating reduced access to external funding compared to the prior year.
• The company reported material weaknesses in internal control over financial reporting that are still being remediated.

Risks

• Ability to successfully identify and acquire additional businesses.
• Ability to effectively integrate and operate acquired businesses.
• Performance of current businesses.
• Ability to maintain business model and improve capital efficiency.
• Ability to effectively manage business growth.
• Ability to maintain profitability.
• Competitive environment in which businesses operate.
• Trends in the industries in which businesses operate.
• Regulatory environment in which businesses operate.
• Ability to service and comply with the terms of indebtedness.
• Ability to retain or replace qualified employees of businesses.
• Labor disputes, strikes or other employee disputes or grievances.
• Casualties, condemnation or catastrophic failures with respect to any business facilities.
• Costs and effects of legal and administrative proceedings, settlements, investigations and claims.
• Extraordinary or force majeure events affecting the business or operations.
• Inability to obtain sufficient capital from debt or equity transactions or from operations in the necessary time frame or on terms acceptable.
• Potential requirement to curtail operating plans or implement cost reductions if sufficient funds are not raised.
• Cessation of operations if sufficient funds are not raised.
• Risk of not collecting accounts receivable if no settlement is reached with the defendant's insurance company or if the patient's case is abandoned (historically less than 1.0% loss rate).
• Risk of accepting lower settlement realization rates for faster cash payments on accounts receivable.

Future Outlook

Management is actively seeking additional capital through new financing and equity raises to fund operations and pursue new acquisitions, targeting 80% of its portfolio in established profitable niche healthcare companies and 20% in second-stage healthcare and financial services startups. The company plans to enter a joint venture for its Salmon, Idaho real estate development. Compensation for key executives is tied to future milestones, including successful acquisitions and a Nasdaq listing with a $4 million capital raise. The company will continue to evaluate and update its settlement realization rates for accounts receivable quarterly.

Management Comments

• We believe, based on our operating plan, that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy our obligations as they come due for at least one year from the financial statement issuance date.
• Additional funds from new financing and/or future equity raises are required for continued operations and to execute our business plan and our strategy of acquiring additional businesses.
• The funds required to sustain operations range between $600,000 to $1 million, and additional funds to execute our business plan will depend on the size, capital structure, and purchase price consideration that the seller of a target business deems acceptable in a given transaction.
• We intend to raise capital for additional acquisitions primarily through equity and debt financings.
• To help the segments achieve optimal operating performance, management retains the prior owners of the subsidiaries and allows them to do what they do best, which is run the business.
• Management has invested years working to develop a new and exciting housing development in Salmon, Idaho and plans to enter into a joint venture agreement with a developer for this planned concept development.

Industry Context

Cardiff Lexington operates primarily in the niche healthcare sector, focusing on orthopedic care for traumatic injury victims, often utilizing a lien-based model where payments are derived from insurance settlements. This model provides some insulation from direct patient billing risks but ties revenue realization to legal settlement timelines. The company's strategy as an acquisition holding company aims for diversification and risk mitigation by acquiring undervalued and undercapitalized companies, particularly within healthcare. Its real estate segment, Edge View Properties, Inc., is focused on land development, which is subject to local housing market dynamics and development cycles. The company's financial performance, particularly its reliance on financing and its accumulated deficit, suggests it is in a growth or restructuring phase, common for acquisition holding companies, but with significant financial challenges.

Comparison to Industry Standards

• The company's historical accounts receivable collection rate of 99% (less than 1% loss rate) in the lien-based medical industry is strong, indicating effective management of this specific revenue stream.
• However, efforts to accelerate cash settlement in 2024 resulted in a lower average settlement rate of 42.9% of gross billed charges, compared to a historical 49%, suggesting a trade-off between speed of cash collection and the total amount realized, which may be below optimal industry benchmarks for full realization.
• The company's accumulated deficit of over $73 million and ongoing 'going concern' warning indicate that its financial health and profitability metrics are significantly below industry standards for established, stable companies in both the healthcare and real estate sectors.
• The high reliance on debt financing, particularly the revolving line of credit, and the explicit need for substantial additional capital raises, suggest a capital structure that is not self-sustaining, unlike many mature industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• Management is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on the company's business, financial condition, or operating results.

Related Party Transactions

• Due from previous owners of Edge View (current managers): $4,979 as of March 31, 2025 and December 31, 2024.
• A twelve-month convertible promissory note in the principal amount of $5,000 was issued to the company's CEO on August 25, 2023, and was paid in full in August 2024.
• Accrued compensation for Alex Cunningham (CEO) totaled $2,215,500 as of March 31, 2025, with $27,314 in interest accrued for the three months ended March 31, 2025.
• Accrued compensation for Daniel Thompson (Chairman) totaled $2,320,500 as of March 31, 2025, with $28,609 in interest paid for the three months ended March 31, 2025.
• Management agreements with Nova principals (three doctors) include annual base salaries and potential annual cash bonuses and stock equity conditioned on achieving financial performance goals.

Stakeholder Impact

• Shareholders face significant dilution from past and potential future equity issuances, as evidenced by the substantial increase in weighted average shares outstanding.
• Shareholders are exposed to increased financial risk due to the widening net loss, high interest expense, and the company's 'going concern' warning.
• Employees and management have new or amended employment agreements with defined salaries and performance-based bonuses, some tied to future capital raises and company milestones.
• Creditors, particularly holders of the line of credit and convertible notes, face increased risk given the company's accumulated deficit and reliance on future capital raises for liquidity.
• Customers (patients) in the healthcare segment are subject to the company's revenue realization practices, which may involve accepting lower settlement rates for faster payments.

Next Steps

• Continue efforts to raise additional capital from prospective investors through debt or equity financings.
• Pursue new acquisitions, primarily in the healthcare industry, focusing on established profitable niche companies and second-stage startups.
• Enter into a joint venture agreement with a developer for the planned housing development in Salmon, Idaho.
• Continue to evaluate and update the estimate of settlement realization rates for accounts receivable quarterly.
• Implement and complete remediation procedures for identified material weaknesses in internal control over financial reporting, including strategic hiring, training, documentation, segregation of duties, and independent reviews.

Key Dates

Recommendation

Despite revenue growth and improved gross margin, the company's financial health is severely challenged, evidenced by a widening net loss, a substantial increase in interest expense, and a declining cash position. The explicit 'going concern' warning, coupled with a significant accumulated deficit and material weaknesses in internal controls, signals profound financial instability. While management plans capital raises, there is no assurance of success, and any equity raise would likely lead to further substantial dilution for existing shareholders. The high reliance on debt and the inability to generate sustainable positive cash flow from operations make this investment highly speculative and risky.

Keywords

Healthcare, Orthopedic, Real Estate, Acquisition Holding Company, SEC Filing, 10-Q/A, Financial Results, Revenue Growth, Net Loss, Cash Flow, Debt, Convertible Notes, Preferred Stock, Corporate Governance, Internal Controls, Going Concern, Dilution, Financial Reporting